Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 2Gynecologic 1

Conditions

Colorectal Neoplasms 2Colorectal and Ovarian Cancer Patients With Liver Metastases 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 216Irinotecan 185Cisplatin 143Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 41Cyclophosphamide 39trifluridine tipiracil drug combination 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Abituzumab × Gastrointestinal × Clear all
NCT03688230 2020-03-18

AMELION

SFJ Pharmaceuticals, Inc.

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT01008475 2016-03-30

POSEIDON

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
232 enrolled 20 charts
Gastrointestinal

Colorectal Neoplasms

NCT00848510 2015-12-14

EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
41 enrolled 18 charts
GastrointestinalGynecologic

Colorectal and Ovarian Cancer Patients With Liver Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡